Floatz logo

TRASTUZUMAB

HER2 Positive Solid Tumors

Enliven Therapeuticsmonoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the HER2 Positive Solid Tumors cohort.

Asset / SponsorPhaseRating
Epirubicin
Silverback Therapeutics
Phase 1CC
Capecitabine
Enliven Therapeutics
Phase 1CC
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
Silverback Therapeutics
Phase 1CC
Pembrolizumab
Silverback Therapeutics
Phase 1CC
Eloxatin
Enliven Therapeutics
Phase 1CC

View all 11 →

Same molecule, other indications

TRASTUZUMAB is also rated in:

breast carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
inflammatory breast carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
HER2/Neu PositiveDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →